KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Asset Writedowns and Impairment (2016 - 2019)

Arbutus Biopharma (ABUS) has disclosed Asset Writedowns and Impairment for 5 consecutive years, with $43.8 million as the latest value for Q3 2019.

  • Quarterly Asset Writedowns and Impairment rose 195.97% to $43.8 million in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $43.8 million through Dec 2020, down 25.25% year-over-year, with the annual reading at $43.8 million for FY2019, 195.97% up from the prior year.
  • Asset Writedowns and Impairment hit $43.8 million in Q3 2019 for Arbutus Biopharma, up from $14.8 million in the prior quarter.
  • In the past five years, Asset Writedowns and Impairment ranged from a high of $156.3 million in Q2 2016 to a low of $1.0 million in Q4 2015.
  • Historically, Asset Writedowns and Impairment has averaged $55.9 million across 5 years, with a median of $40.8 million in 2017.
  • Biggest five-year swings in Asset Writedowns and Impairment: soared 9425.37% in 2016 and later plummeted 57.89% in 2017.
  • Year by year, Asset Writedowns and Impairment stood at $1.0 million in 2015, then skyrocketed by 9425.37% to $96.9 million in 2016, then tumbled by 57.89% to $40.8 million in 2017, then crashed by 63.7% to $14.8 million in 2018, then skyrocketed by 195.97% to $43.8 million in 2019.
  • Business Quant data shows Asset Writedowns and Impairment for ABUS at $43.8 million in Q3 2019, $14.8 million in Q3 2018, and $40.8 million in Q4 2017.